{"schema_version":"secwatch.filing_event.v1","accession":"0001552000-22-000040","form_type":"8-K","ticker":"MPLX","cik":"0001552000","company_name":"MPLX LP","filed_at":"2022-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.115573+00:00","generated_at":"2026-06-23T04:23:10.366714+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MPLX CEO Hennigan reports no sign of cancer after treatment","bullets":["CEO Michael Hennigan says tests show no sign of throat cancer following treatment.","Completed seven-week radiation and chemotherapy protocol a few months ago.","Prognosis is excellent; he will continue to be monitored as a routine precaution.","Hennigan remains Chairman, President and CEO and is focused on leading MPLX."],"urls":{"canonical":"https://secwatch.observer/filing/0001552000-22-000040","json":"https://secwatch.observer/filing/0001552000-22-000040.json","markdown":"https://secwatch.observer/filing/0001552000-22-000040.md","text":"https://secwatch.observer/filing/0001552000-22-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1552000/000155200022000040/0001552000-22-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1552000/000155200022000040/mplx-20221011.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:23:10.366714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}